help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on January 31, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-1453
A more recent version of this article appeared on April 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/4/1566    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perraudin, V.
Right arrow Articles by Kuhn, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perraudin, V.
Right arrow Articles by Kuhn, J.-M.

Submitted on June 30, 2005
Accepted on January 23, 2006

Evidence for a Role of Vasopressin in the Control of Aldosterone Secretion in Primary Aldosteronism: In Vitro and In Vivo Studies

Véronique Perraudin, Catherine Delarue, Hervé Lefebvre, Jean-Luc Do Rego, Hubert Vaudry*, and Jean-Marc Kuhn

INSERM U 413, Laboratory of Cellular and Molecular Neuroendocrinology, European Institute for Peptide Research (IFRMP 23), University of Rouen (V.P., C.D., H.L., J.L.D.R., H.V., J.M.K.), 76821 Mont-Saint-Aignan, France; INSERM Center for Clinical Investigation 204, University Hospital of Rouen (H.L., J.M.K.), 76031 Rouen, France

* To whom correspondence should be addressed. E-mail: hubert.vaudry{at}univ-rouen.fr.

Context: Arginine vasopressin (AVP) stimulates steroid secretion from the normal human adrenal gland and some cortisol-producing adrenocortical tumors or hyperplasia through activation of the V1a receptor.

Objective: To investigate in vitro and in vivo the possible involvement of AVP in the physiopathology of primary aldosteronism (PA).

Design: Immunohistochemical, pharmacological and molecular studies on aldosterone- producing adenoma (APA), followed by a monocentric, cross-over trial of the orally active V1a receptor antagonist, SR 49059, in a double blind, randomized and placebo-controlled fashion.

Setting: University hospital and research laboratory.

Patients: Eight untreated patients with PA, four with APA and four with idiopathic hyperaldosteronism (IH).

Main outcome measures: Aldosterone secretion of APA cells in vitro; plasma aldosterone, renin and ACTH.

Intervention: SR 49059 (200 mg once daily) or placebo during 2 one-week treatment periods separated by a two-week washout.

Results: We observed the occurrence of AVP-containing cells in APA tissues. Administration of AVP to perifused APA cells induced an increase in aldosterone production which was inhibited by a specific V1a antagonist. RT-PCR analysis showed the expression of V1a receptor mRNA in most APA studied. In APA patients, SR 49059 did not induce any effect on basal aldosterone secretion but provoked a plasma aldosterone response to orthostatism (P < 0.03) and strengthened the positive correlation between plasma aldosterone and ACTH.

Conclusion: The present study indicates that functionnal V1a receptors are present in APA and suggests that AVP may exert an autocrine/paracrine control of aldosterone secretion in APA tissues.
Key words: AVP • V1a vasopressinergic receptor • non peptidic V1a receptor antagonist • aldosterone-producing adenoma • idiopathic hyperaldosteronism • aldosterone secretion




This article has been cited by other articles:


Home page
 J EndocrinolHome page
P. Ye, B. Mariniello, F. Mantero, H. Shibata, and W. E Rainey
G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism
J. Endocrinol., October 1, 2007; 195(1): 39 - 48.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Aoyagi, J.-i. Birumachi, M. Hiroyama, Y. Fujiwara, A. Sanbe, J. Yamauchi, and A. Tanoue
Alteration of Glucose Homeostasis in V1a Vasopressin Receptor-Deficient Mice
Endocrinology, May 1, 2007; 148(5): 2075 - 2084.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D Vezzosi, D Cartier, C Regnier, P Otal, A Bennet, F Parmentier, M Plantavid, A Lacroix, H Lefebvre, and P Caron
Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors
Eur. J. Endocrinol., January 1, 2007; 156(1): 21 - 31.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society